What did @azulayomri actually say?
Honestly, this is a tough one to fact-check. The transcript from this video is almost entirely incoherent, likely the result of an automated translation from Hebrew that produced near-nonsense English. The caption, however, is clear: this video is about "appetite peptide, mass and fat burning simultaneously" and tags GHRP peptides specifically. So we're working with a caption claim and a category, not a clean spoken argument.
The core claim, based on the caption, appears to be that GHRP peptides can simultaneously support muscle mass and fat loss. That's a real claim made frequently in peptide communities, and it's worth examining seriously, even if the transcript itself gave us nothing usable to quote directly.
Does the science back this up?
Partially, and with important caveats. GHRP (Growth Hormone Releasing Peptides) like GHRP-2 and GHRP-6 work by binding to the ghrelin receptor, stimulating the pituitary to release growth hormone. The appetite-stimulating angle is real: ghrelin is literally the hunger hormone, and GHRP-6 in particular is well-documented to increase appetite significantly.
The body composition angle is more nuanced. Growth hormone does have lipolytic (fat-breaking) effects and supports lean mass, but the downstream effects of GHRP use depend heavily on baseline GH levels, diet, training, and which specific peptide is used. GHRP-2 causes less appetite stimulation than GHRP-6, which matters if fat loss is a goal. A study by Laferrere et al. (2005, Journal of Clinical Endocrinology and Metabolism) confirmed that GHRP-2 robustly stimulates GH secretion in humans, but did not demonstrate body recomposition outcomes in isolation. The "recomp" narrative is plausible mechanistically, not proven clinically.
What did they get wrong (or right)?
The caption framing gets credit for at least being directionally accurate. GHRPs do affect appetite via ghrelin pathways, and GH has documented effects on both fat metabolism and protein synthesis. That much is grounded in real physiology.
What's missing, and this matters, is the specificity. Saying "appetite peptide, mass and fat burning simultaneously" flattens a genuinely complicated picture into a simple promise. Here's what that framing leaves out:
- GHRP-6 increases appetite significantly, which can work against fat loss if calories are not managed.
- GHRP-2 is less appetite-stimulating but still carries risks including cortisol and prolactin elevation (Ghigo et al., 1994, European Journal of Endocrinology).
- Most GHRP studies are short-term, conducted in GH-deficient populations, or in animal models. Extrapolating to healthy adults for body recomposition is a significant leap.
- These peptides are not approved by the FDA for these uses. Compounded versions vary in purity and dosing accuracy.
The simultaneous muscle gain and fat loss framing is the kind of claim that sounds scientific but gets far ahead of the actual human trial data.
What should you actually know?
If you're seeing GHRP content on TikTok, here's what the research actually supports versus what's being sold. GHRPs are real pharmacological compounds with measurable effects on GH pulse amplitude. They are not supplements. They carry real side effects: water retention, increased cortisol, elevated prolactin, and hunger (especially GHRP-6).
The "recomp" claim, building muscle while burning fat simultaneously, is one of the most aggressively marketed ideas in the peptide space. It is physiologically possible under specific conditions but is not reliably achieved through peptide use alone in healthy adults with normal GH levels. A 2020 review by Goldenberg and Hayes in the Journal of the International Society of Sports Nutrition noted that GH secretagogues show limited evidence for body composition benefits in non-deficient individuals.
Anyone considering GHRP compounds should be working with a licensed clinician who can order baseline IGF-1 labs, monitor for side effects, and evaluate whether there's a clinical rationale. Social media peptide content, especially when translated through an unreliable auto-transcription, is not a clinical consultation.